We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

79 hedge funds and large institutions have $546M invested in Crinetics Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

575% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 4

413% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 8

78% more capital invested

Capital invested by funds: $307M → $546M (+$240M)

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

41% more funds holding

Funds holding: 56 → 79 (+23)

10.82% more ownership

Funds ownership: 84.92% → 95.74% (+11%)

Holders
79
Holders Change
+23
Holders Change %
+41.07%
% of All Funds
1.62%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.1%
New
27
Increased
41
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
+$34.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.4M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$18.3M
4
PA
Perceptive Advisors
New York
+$18.3M
5
BlackRock
BlackRock
New York
+$17.8M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$17.1M
2
5VM
5AM Venture Management
California
-$8.52M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$7.23M
4
Victory Capital Management
Victory Capital Management
Texas
-$5.21M
5
BCM
Burrage Capital Management
Massachusetts
-$782K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$2.74M +$2.19M +128,522 +458%
NLVP
27
New Leaf Venture Partners
New York
$2.47M – – –
Charles Schwab
28
Charles Schwab
California
$2.37M +$1.4M +82,252 +156%
CCM
29
CAAS Capital Management
New York
$2.06M +$2M +117,414 New
Millennium Management
30
Millennium Management
New York
$1.98M +$1.93M +113,034 New
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$1.51M +$983K +57,660 +203%
Victory Capital Management
32
Victory Capital Management
Texas
$1.12M -$5.21M -305,690 -83%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$960K +$609K +35,700 +187%
Two Sigma Investments
34
Two Sigma Investments
New York
$943K +$917K +53,812 New
AA
35
ALPS Advisors
Colorado
$785K +$13.1K +769 +2%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$715K +$402K +23,601 +137%
Swiss National Bank
37
Swiss National Bank
Switzerland
$634K +$297K +17,400 +93%
Renaissance Technologies
38
Renaissance Technologies
New York
$624K +$607K +35,600 New
UBS AM
39
UBS AM
Illinois
$583K +$567K +33,254 New
Citadel Advisors
40
Citadel Advisors
Florida
$579K -$46.2K -2,711 -8%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$572K +$340K +19,959 +157%
AllianceBernstein
42
AllianceBernstein
Tennessee
$454K +$189K +11,100 +75%
HS
43
HighVista Strategies
Massachusetts
$450K +$438K +25,701 New
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$434K +$206K +12,100 +95%
VEA
45
Virtus ETF Advisers
New York
$386K +$375K +22,026 New
Bank of America
46
Bank of America
North Carolina
$365K +$194K +11,398 +121%
Wells Fargo
47
Wells Fargo
California
$355K +$230K +13,497 +200%
HTC
48
Hershey Trust Company
Pennsylvania
$347K +$288K +16,883 +583%
Jane Street
49
Jane Street
New York
$319K +$310K +18,194 New
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$300K – – –
1
2
3 4

CRNX Hedge Fund Activity: Q2 2020 in Review

79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2020, worth a combined $546M — up 78% from $307M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRNX positions and 4 closed out — a net gain of 23 holders — while 41 added to existing stakes and 8 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $34.6M. The largest seller was Vivo Capital, cutting an estimated $17.1M.

  • 79 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2020, up from 56 in Q1 2020.
  • Funds reported $546M of Crinetics Pharmaceuticals stock for Q2 2020, up 78% quarter-over-quarter.
  • 27 funds opened new Crinetics Pharmaceuticals positions in Q2 2020 and 4 closed out, a net change of +23 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q2 2020 was Versant Venture Management, an estimated $34.6M added.
  • The largest Crinetics Pharmaceuticals seller in Q2 2020 was Vivo Capital, an estimated $17.1M sold.

Based on aggregated 13F filings for Q2 2020.